Continuous complete hematological and cytogenetic remission with molecular minimal residual disease 9 years after discontinuation of interferon-α in a patient with Philadelphia chromosome-positive chronic myeloid leukemia

Acta Haematologica

Volumn 115, Issue 1-2, 2006, Pages 109-112

  Verbeek, W ^a   Konig H ^b   Boehm, J ^c   Kohl, D ^a   Lange, C ^a   Heuer, T ^a   Scheibenbogen, C ^d   Reis, H E ^a   Hochhaus, A ^b   Graeven, U ^a  

^a KLINIKEN MARIA HILF GMBH   (Germany)

^b MEDICAL FACULTY MANNHEIM HEIDELBERG UNIVERSITY   (Germany)

^c UNIVERSITY OF FREIBURG   (Germany)

^d CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Chronic myeloid leukemia; Interferon ; Minimal residual disease; Remission, long term

Indexed keywords

ALPHA INTERFERON; ALPHA2B INTERFERON; GAMMA INTERFERON; IMATINIB; PROTEIN TYROSINE KINASE INHIBITOR;

AGED; ARTICLE; BONE MARROW BIOPSY; CANCER IMMUNOTHERAPY; CASE REPORT; CHROMOSOME ANALYSIS; CLINICAL EXAMINATION; CLINICAL FEATURE; CONTROLLED STUDY; HUMAN; HUMAN CELL; LABORATORY TEST; LEUKEMIA REMISSION; MALE; MINIMAL RESIDUAL DISEASE; MYELOID LEUKEMIA; PHILADELPHIA CHROMOSOME POSITIVE CELL; PHYSICAL EXAMINATION; PRIORITY JOURNAL; TREATMENT OUTCOME;

AGED; ANTINEOPLASTIC AGENTS; FOLLOW-UP STUDIES; HUMANS; INJECTIONS, SUBCUTANEOUS; INTERFERON-ALPHA; LEUKEMIA, MYELOID, CHRONIC; LEUKEMIA, MYELOID, PHILADELPHIA-POSITIVE; MALE; NEOPLASM, RESIDUAL; REMISSION INDUCTION; TIME FACTORS;

EID: 31144446854     PISSN: 00015792     EISSN: None     Source Type: Journal    
DOI: 10.1159/000089476     Document Type: Article

References (20)

1. Goldman JM, Marin D, Olavarria E, Apperley JF: Clinical decisions for chronic myeloid leukemia in the imatinib era. Semin Hematol 2003;40:98-103.
2. O'Brien SG, Guilhot F, Larson RA, Gathmann I, Baccarani M, Cervantes F, Cornelissen JJ, Fischer T, Hochhaus A, Hughes T, Lechner K, Nielsen JL, Rousselot P, Reiffers J, Saglio G, Shepherd J, Simonsson B, Gratwohl A, Goldman JM, Kantarjian H, Taylor K, Verhoef G, Bolton AE, Capdeville R, Druker BJ: IRIS Investigators: Imatinib compared with interferon and low dose cytarabine in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003;348:994-1004.
3. The Italian Cooperative Study Group on Chronic Myeloid Leukemia: Interferon alpha 2a as compared with conventional chemotherapy for the treatment of chronic myeloid leukemia. N Engl J Med 1994;330:820-825.
4. Hasford J, Pfirrmann M, Hehlmann R, Allan NC, Baccarani M, Kluin-Nelemans JC, Alimena G, Steegmann JL, Ansari H: A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alpha. Writing Committee for the Collaborative CML Prognostic Factors Project Group. J Natl Cancer Inst 1998;90:850-858.
5. Bonifazi F, de Vivo A, Rosti G, Guilhot F, Guilhot J, Trabacchi E, Hehlmann R, Hochhaus A, Shepherd PC, Steegmann JL, Klui-Nelemans HC, Thaler J, Simonsson B, Louwagie A, Reiffers J, Mahon FX, Montefuso E, Alimena G, Hasford J, Richards S, Saglio G, Testoni N, Martinelli G, Tura S, Baccarani M; Europena Study Group on Interferon in Chronic Myeloid Leukemia; Italian Cooperative Study Group on CML, France Intergroup of CML; German CML Study Group; UK Medical Research Council Working Party on CML; Spanish CML Study Group; Australian CML Study Group; Swedish CML Study Group: Chronic myeloid leukemia and interferon-alpha: a study of cytogenetic responders. Blood 2001;98:3074-3081.
6. Kantarjian HM, O'Brien S, Cortes JE, Shan J, Giles FJ, Rios MB, Faderl S, Wierda WG, Ferrajoli A, Verstovsek S, Keating MJ, Freireich EJ, Talpaz M: Complete cytogenetic and molecular responses to interferon-based therapy for chronic myelogenous leukemia are associated with excellent long term prognosis. Cancer 2003;97:1033-1041.
7. Burmeister T, Maurer J, Aivado M, Elmaagacli AH, Grunebach F, Held KR, Hess G, Hochhaus A, Hoppner W, Lentes KU, Lubbert M, Schafer KL, Schafhausen P, Schmidt CA, Schuler F, Seeger K, Seelig R, Thiede C, Viehmann S, Weber C, Wilhelm S, Christmann A, Clement JH, Ebener U, Enczmann J, Leo R, Schleunig M, Schoch R, Thiel E: Quality assurance in RT-PCR-based BCR/ABL diagnostics - results of an interlaboratory test and a standardisation approach. Leukemia 2000;14:1850-1856.
8. Cross NC, Hughes TP, Feng L, O'Shea, Bungey J, Marks DI, Ferrant A, Martiat P, Goldman JM: Minimal residual disease after allogeneic bone marrow transplantation for chronic myeloid leukemia in first chronic phase: correlations with acute graft versus host disease and relapse. Br J Haematol 1993;84:67-74.
9. Emig M, Sausele S, Wittor H, Weisser A, Reiter A, Willer A, Berger U, Hehlmann R, Cross NC, Hochhaus A: Accurate and rapid analysis of residual disease in patients with CML using specific fluorescent hybridisation probes for real time quantitative RT-PCR. Leukemia 1999;13:1825-1832.
10. Hochhaus A, Lin F, Reiter A, Skladny H, Mason PJ, van Rhee F, Shepherd PC, Allan NC, Hehlmann R, Goldman JM, Cross NC: Quantification of residual disease in chronic myelogenous leukemia patients on interferon alpha therapy by competitive polymerase chain reaction. Blood 1996;87:1549-1555.
11. Scheibenbogen C, Letsch A, Thiel E, Schmittel A, Mailaender V, Baerwolf S, Nagorsen D, Keilholz U: CD 8 T-cell responses to Wilms tumor gene product WT1 and proteinase 3 in patients with acute myeloid leukemia. Blood 2002;100:2132-2137.
12. Molldrem JJ, Lee PP, Wang C, Felio K, Kantarjian HM, Champlin RE, Davis MM: Evidence that specific T lymphocytes may participate in the elimination of chronic myelogenous leukemia. Nat Med 2000;6:1018-1023.
13. Ohminami H, Yasukawa M, Fujita S: HLA class I-restricted lysis of leukemia cells by a CD8+ cytotoxic T-lymphocyte clone specific WT1 peptide. Blood 2000;95:286-293.
14. Azuma T, Akita M, Ninomiya K, Fujita S, Harada M, Yasukawa M: Identification of a novel WT 1-derived peptide which induces human leucocyte antigen-A24-restricted antileukaemia cytotoxic T-lymphocytes. Br J Haematol 2002;116:601-603.
15. Burchert A, Wofl S, Schmidt M, Brendel C, Denecke B, Cai D, Odyvanova L, Lahaye T, Muller MC, Berg T, Gschaidmeier H, Wittig B, Hehlmann R, Hochhaus A, Neubauer A: Interferon-alpha, but not the Abl-kinase inhibitor imatinib induces expression of myeloblastin and a specific T-cell response in chronic myeloid leukemia. Blood 2003;101:259-264.
16. Paschka P, Muller MC, Merx K, Kreil S, Schoch C, Lahaye T, Weisser A, Petzold A, Konig H, Berger U, Gschaidmeier H, Hehlmann R, Hochhaus A: Molecular monitoring of response to imatinib (Glivec) in CML patients pretreated with interferon alpha. Low levels of residual disease are associated with continuous remission. Leukemia 2003;17:1687-1694.
17. Rosti G, Martinelli G, Bassi S, Amabile M, Trabacchi E, Giannini B, Izzo B, De Vivo A, Testoni N, Cambrin GR, Bonifazi F, Soverini S, Gottardi E, Alberti D, Pane F, Salvatore F, Saglio G, Baccarani M; Study Committee, Italian Cooperative Study Group for Chronic Myeloid Leukemia; Writing Committee, Italian Cooperative Study Group for Chronic Myeloid Leukemia: Molecular response to imatinib in late chronic-phase chronic leukemia. Blood 2004;103:2284-2290.
18. Kantarjian HM, Talpaz M, Cortes J, O'Brien S, Faderl S, Thomas D, Rios MB, Shan J, Arlinghaus R: Quantitative polymerase chain reaction monitoring of BCR/ABL during therapy with imatinib mesylate (STI 571; Gleevec) in chronic phase chronic myelogenous leukemia. Clin Cancer Res 2003;9:160-166.
19. Mauro MJ, Druker BJ, Maziarz RT: Divergent clinical outcome in two CML patients who discontinued imatinib therapy after achieving a molecular remission. Leuk Res 2004;28:71-73.
20. Baccarani M, Martinelli G, Rosti G, Trabacchi E, Testoni N, Bassi S, Amabile M, Soverini S, Castagnetti F, Cilloni D, Izzo B, de Vivo A, Messa E, Bonifazi F, Poerio A, Luatti S, Giugliano E, Alberti D, Fincato G, Russo D, Pane F, Saglio G; GIMEMA Working Party on Chronic Myeloid Leukemia: Imatinib and pegylated human recombinant interferon-α2b in early chronic-phase chronic myeloid leukemia. Blood 2004;104:4245-4251.